Hofer Markus
Clinic for Pulmonary Medicine, University Hospital, Zurich, Switzerland.
Swiss Med Wkly. 2007 Nov 3;137(43-44):593-601. doi: 10.4414/smw.2007.11680.
Modern treatment of patients with advanced lung disease includes not only pulmonary therapy but also integrative treatment of co-morbidities directly or indirectly linked to the underlying lung disease. Moreover, impairment of heath related quality of life is frequent in these patients and influences their physical and psychological "well-being". Therefore, a multidisciplinary team approach gives the opportunity to appropriately deal with all these issues. It has been shown that treating patients with advanced lung disease in specialised centres has a positive impact on survival, especially for patients with CF and IPF. Referral to the intensive care unit is not generally contraindicated and mortality depends on the underlying lung disease and co-morbidities. Nowadays, lung transplantation is a valuable therapeutic option in advanced lung disease and should be considered early especially in IPF patients.
晚期肺部疾病患者的现代治疗不仅包括肺部治疗,还包括对与潜在肺部疾病直接或间接相关的合并症进行综合治疗。此外,这些患者的健康相关生活质量经常受到损害,并影响他们的身心“幸福感”。因此,多学科团队方法为妥善处理所有这些问题提供了机会。已经表明,在专门的中心治疗晚期肺部疾病患者对生存率有积极影响,尤其是对于囊性纤维化(CF)和特发性肺纤维化(IPF)患者。一般而言,转入重症监护病房并无禁忌,死亡率取决于潜在的肺部疾病和合并症。如今,肺移植是晚期肺部疾病的一种有价值的治疗选择,尤其对于IPF患者,应尽早考虑。